Skip to main content
. 2021 Dec 4;19:95. doi: 10.1186/s12959-021-00339-x

Table 1.

Demographics and Characteristics of Patients

Variables LC(n = 1090) LC-VTE (n = 173) P value
Age-years 68.5 (47.6–86.3) 72.2 (51.5–88.6) 0.723
Sex (female/male)-% 43.0/57.0 46.8/53.2 0.915
BMI-kg/m2 21.9 (17.5–27.3) 29.6 (24.3–34.7) 0.013
Smoking (Y/N)-% 40.1/59.9 50.9/49.1 0.009
Smoking index-pack/year 33.6 (21.3–45.9) 47.3 (30.6–63.7) 0.001
Histopathology-no.(%)
 Adenocarcinoma 673 (61.7) 109 (63.0) 0.537
 Squamous 269 (24.7) 40 (23.1) 0.941
 SCLC 123 (11.3) 17 (9.80) 0.713
 Others 25 (2.30) 7 (4.10) 0.025
Stage-no.(%)
 Stage I 199 (18.3) 3 (1.70) < 0.001
 Stage II 227 (20.8) 33 (19.1) 0.985
 Stage III 257 (23.6) 44 (25.4) 0.836
 Stage IV 407 (37.3) 93 (53.8) 0.001
High or intermediate
 C-PTP(Y/N)-% 45.2/54.8 74.6/25.4 < 0.001
 D-dimer-mg/L 3713 (2336–5369) 1331 (854–1776) < 0.001
 Platelet- × 109/L 387 (226–543) 252 (157–357) 0.001
 Hemoglobin-g/L 97 (83–114) 109 (91–127) 0.573
 WBC- × 109/L 13.1 (7.62–18.6) 7.73 (4.38–11.1) 0.001
 Chemotherapy(Y/N)-% 65.8/34.2 94.2/5.8 < 0.001
 PS score-point 1.35 (0.66–2.25) 2.31 (1.23–3.47) 0.005
 Metastasis(Y/N)-% 37.3/62.7 53.8/46.2 0.001
 Previous VTE(Y/N)-% 9.9/90.1 17.9/82.1 0.001
 Vascular/lymphatic compression(Y/N)-% 70.1/29.9 90.8/9.2 < 0.001
 Anti-hormonal or anthracycline therapy(Y/N)-% 2.0/98.0 1.7/98.3 0.896
 Time since cancer diagnosis≤6 months(Y/N)-% 49.8/50.2 52.6/47.4 0.916
 CVC(Y/N)-% 3.9/96.1 9.8/90.2 < 0.001
 Cardiovascular risk factors(Y/N)-% 15.0/85.0 29.5/70.5 < 0.001
 Recent hospitalization (Y/N)-% 66.5/33.5 97.7/2.3 < 0.001

Note: LC: Lung Cancer, LC-VTE:Lung Cancer and Venous Thromboembolism, no.:number, BMI: Body Mass Index, kg/m2: kilogram/meter2, Y/N:Yes/No, SCLC: Small Cell Lung Cancer, C-PTP: Clinical Pretest Probability, mg/L:milligram/liter, L:liter, WBC: White Blood Cell, PS: Performance Status, VTE:Venous Thromboembolism, CVC: Central Venous Catheter